668470-83-5

Upstream product

• 800407-89-0 (2S,3R)-4-benzyl-2-(hydroxyphenylmethyl)morpholin-3-one 
• 800407-88-9 (2S)-2-[(S)-hydroxy(phenyl)methyl]-4-(phenylmethyl)morpholin-3-one 
• 98-88-4 benzoyl chloride 
• 1468-28-6 4-benzoylmorpholine 
• 800407-90-3 (2R,3S)-4-benzyl-2-(hydroxyphenylmethyl)morpholin-3-one 
• 918656-67-4 (1S,2S)-3-(N-benzyl-N-(2-chloroethyl)amino)-1-phenylpropane-1,2-diol 
• 857642-79-6 C₁₈H₁₉NO₃ 
• 664361-10-8 (2S)-(4-benzyl-morpholin-2-yl)-phenyl-methanone 

Downstream Products

• 667876-79-1 (2S,3R)-4-benzyl-2-(bromophenylmethyl)morpholine 
• 667876-78-0 (2R,3S)-4-benzyl-2-(bromophenylmethyl)morpholine 
• 918657-06-4 (2S,3S)-4-benzyl-2-[(2-ethoxyphenoxy)phenylmethyl]morpholine 
• 71620-89-8 (S,S)-reboxetine 

Relevant academic research and scientific papers

Dynamic kinetic resolution-based asymmetric transfer hydrogenation of 2-benzoylmorpholinones and its use in concise stereoselective synthesis of all four stereoisomers of the antidepressant reboxetine

Dynamic kinetic resolution-driven, asymmetric transfer hydrogenation reaction of 2-benzoylmorpholin-3-ones (4) proceeds efficiently to give the corresponding (2R,3S)- or (2S,3R)-2-(hydroxyphenylmethyl)morpholin-3-ones (6) with an excellent level of diastereo- and enantioselectivity and simultaneous control of two contiguous stereogenic centers in a single step. This process is employed to prepare all four stereoisomers of the antidepressant reboxetine.

NOREPINEPHRINE TRANSPORTER RADIOTRACERS AND METHODS OF SYNTHESES THEREOF

The present invention provides compounds and radiotracers thereof for locating, diagnosing, identifying, evaluating, detecting or quantitating NET by in vivo imaging. The invention also provides methods for locating, diagnosing, identifying, evaluating, detecting or quantitating NET, using radiotracers of high-affinity or labeled compounds of the invention, which exhibit low toxicity, can cross the blood-brain barrier and, preferably, distinguish among normal and abnormal brains. For example, a radiotracer of the invention can be administered to a patient in an amount suitable for in vivo imaging thereof. Preferably, radiotracers of the invention can also be used to locate, diagnosis, identify, evaluate, detect and quantitate NET in such diseases, disorders, conditions or maladies as, without limitation, depression, anxiety, ADHD and drug dependency.

TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH NOREPINEPHRINE REUPTAKE INHIBITORS

Provided are methods and medicaments for treating a Pervasive Developmental Disorder, comprising administering to a patient in need of such treatment an effective amount of a selective norepinephrine reuptake inhibitor.

TREATMENT OF HOT FLASHES, IMPULSE CONTROL DISORDERS AND PERSONALITY CHANGE DUE TO A GENERAL MEDICAL CONDITION

Selective norepinephrine reuptake inhibitors are useful for the prevention or treatment of hot flashes, vasomotor symptoms, impulse control disorders or personality change due to a general medical condition.

TREATMENT OF LEARNING DISABILITIES AND MOTOR SKILLS DISORDER WITH NOREPINEPHRINE REUPTAKE INHIBITORS

Provided are methods and medicaments for treating a learning disability or a Motor Skills Disorder, comprising administering to a patient in need of such treatment an effective amount of a selective norepinephrine reuptake inhibitor.

PYRIDINYLMORPHOLINE DERIVATIVES

The invention relates to compounds of formula (I); wherein R, R1, R2 and X are as defined herein, their preparation and their use as pharmaceuticals.

BENZYL MORPHOLINE DERIVATIVES

A compound of formula (I) (I)wherein R is H; Ar is an aromatic group selected from phenyl; X is a phenyl group; R' is H or C1-C4 alkyl; each R1 is independently H or C1-C4 alkyl; and pharmaceutically acceptable salts thereof.

MORPHOLINE DERIVATIVES

Compounds of formula (I), wherein: A is S or O; R is H; Ar is an optionally substituted phenyl group; X is an optionally substituted phenyl group, a C1-C4 alkyl, a C3-C6 cycloalkyl group or a CH2(C3-C6 cycloalkyl) group; R' is H or C1-C4 alkyl; and each R